One day of intranasal UCT-MSC-EXs therapy began in November 2022, and his second 1-day treatment of intranasal UCT-MSC-EXs began in January 2023
Brain Res 448:369372 [DOI] [PubMed] [Google Scholar] Di L, Kerns EH, Gao N, Li SQ, Huang Y, Bourassa JL, Huryn DM
Solutions for Chronic Inflammation with GLOW Peptide Therapy: The GLOW Peptide protocol directly targets this inflammatory cascade
Regenerative research applications This peptide is also explored in broader regenerative research contexts, supporting studies into biological response systems under controlled laboratory conditions
USPTO Patents Pending
Wells Fargo & Company (WFC) reported Q4 and full-year 2025 results on January 14, 2026, that unfortunately missed consensus estimates on revenue as well as net interest income